Genetically engineered mesenchymal stromal cells producing TNFα have tumour suppressing effect on human melanoma xenograft

2015 ◽  
Vol 17 (1-2) ◽  
pp. 54-67 ◽  
Author(s):  
Silvia Tyciakova ◽  
Miroslava Matuskova ◽  
Roman Bohovic ◽  
Katarina Polakova ◽  
Lenka Toro ◽  
...  
Keyword(s):  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Human Melanoma ◽  
Genetically Engineered ◽  
Human Melanoma Xenograft ◽  
Melanoma Xenograft

scholarly journals Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model

2004 ◽  
Vol 112 (2) ◽  
pp. 329-334 ◽  
Author(s):  
Renate R.J. de Groot-Besseling ◽  
Theo J.M. Ruers ◽  
Annemieke A. van Kraats ◽  
Geert J.M. Poelen ◽  
Dirk J. Ruiter ◽  
...  
Keyword(s):  
Plasminogen Activator ◽  
Xenograft Model ◽  
Human Melanoma ◽  
Human Melanoma Xenograft ◽  
Melanoma Xenograft ◽  
Anti Tumor Activity

Mesenchymal stromal cells genetically engineered to overexpress IGF-I enhance cell-based gene therapy of renal failure-induced anemia

2008 ◽  
Vol 295 (2) ◽  
pp. F488-F496 ◽  
Author(s):  
Terrence Kucic ◽  
Ian B. Copland ◽  
Jessica Cuerquis ◽  
Daniel L. Coutu ◽  
Lorraine E. Chalifour ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Renal Failure ◽  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Heart Function ◽  
Collagen Matrix ◽  
Genetically Engineered ◽  
Functional Protein ◽  
Igf I

We previously demonstrated that erythropoietin (EPO)-secreting mesenchymal stromal cells (MSC) can be used for the long-term correction of renal failure-induced anemia. The present study provides evidence that coimplantation of insulin-like growth factor I (IGF-I)-overexpressing MSC (MSC-IGF) improves MSC-based gene therapy of anemia by providing paracrine support to EPO-secreting MSC (MSC-EPO) within a subcutaneous implant. IGF-I receptor RNA expression in murine MSC was demonstrated by RT-PCR. Functional protein expression was confirmed by immunoblots and MSC responsiveness to IGF-I stimulation in vitro. IGF-I was also shown to improve MSC survival following staurosporin-induced apoptosis in vitro. A cohort of C57Bl/6 mice was rendered anemic by right kidney electrocoagulation and left nephrectomy. MSC-EPO were subsequently admixed in a bovine collagen matrix and implanted, in combination with MSC-IGF or MSC null, by subcutaneous injection in renal failure mice. In mice receiving MSC-EPO coimplanted with MSC-IGF, hematocrit elevation was greater and enhanced compared with control mice; heart function was also improved. MSC-IGF coimplantation, therefore, represents a promising new strategy for enhancing MSC survival within implanted matrices and for improving cell-based gene therapy of renal anemia.

Sign in / Sign up

Export Citation Format

Share Document